Edition:
India

Aptose Biosciences Inc (APTO.OQ)

APTO.OQ on NASDAQ Stock Exchange Capital Market

2.12USD
8:35pm IST
Change (% chg)

$0.02 (+0.95%)
Prev Close
$2.10
Open
$2.12
Day's High
$2.14
Day's Low
$2.12
Volume
13,401
Avg. Vol
40,202
52-wk High
$2.29
52-wk Low
$0.78

Summary

Name Age Since Current Position

William Rice

2013 Chairman of the Board, President, Chief Executive Officer

Gregory Chow

2014 Chief Financial Officer, Senior Vice President

Denis Burger

70 2011 Independent Director

Erich Platzer

2014 Independent Director

Bradley Thompson

2013 Independent Director

Mark Vincent

2007 Independent Director

Warren Whitehead

2011 Independent Director

Biographies

Name Description

William Rice

Dr. William G. Rice, Ph.D., has been appointed as Chairman of the Board, President, Chief Executive Officer of Aptose Biosciences Inc., with effect from October 28, 2013. Prior to joining Lorus, Dr. Rice served as the President, Chief Executive Officer and Chairman of the board of Cylene Pharmaceuticals, Inc., a private biotechnology company (“Cylene”). Prior to Cylene, Dr. Rice was the founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. He also served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute- Frederick Cancer Research and Development Center, and served as a faculty member in the division of Pediatric Hematology and Oncology at Emory University School of Medicine. Dr. Rice received his Ph.D. from Emory University Department of Biochemistry. He also serves as the Chairman of the board of Cylene.

Gregory Chow

Mr. Gregory K. Chow is Chief Financial Officer, Senior Vice President of Aptose Biosciences Inc. Previously, Mr. Chow served as Managing Director, Director of Private Placements at Wedbush Securities, where he led the private placement capital activities within the Life Sciences Investment Banking Group. Prior to joining Wedbush, he was a Director in the Private Placements / Equity Capital Markets Group at RBC Capital Markets, where he led life science private capital activities. Previously, he led the Private Capital Group at Wells Fargo Securities and was a Senior Auditor at BDO Seidman, LLP in their Century City, CA office. Mr. Chow is a Certified Public Accountant (inactive) in the State of California. Mr. Chow received his MBA in Finance from The Wharton School at the University of Pennsylvania, and his BA in Business Economics with an emphasis in Accounting from the University of California, Santa Barbara.

Denis Burger

Dr. Denis R. Burger, Ph.D., is Independent Director of Aptose Biosciences Inc. Dr. Burger is currently the executive Chairman of BioCurex, Inc. Dr. Burger was the past Chairman, Chief Executive Officer and a director of AVI Biopharma Inc, an Oregon based biotechnology company from 1992 to March 2007. Dr. Burger is also a partner in Sovereign Ventures, a healthcare consulting and funding firm based in Portland, Oregon. Dr. Burger received his MSc and PhD in Microbiology and Immunology from the University of Arizona. Dr. Burger is also currently on the Board of Trinity Biotech plc. and BioCurex, Inc.Executive Chairman, BioCurex, Inc. (2009 to present) (biotechnology company).

Erich Platzer

Dr. Erich M. Platzer M.D., Ph.D., has been appointed as Director of Aptose Biosciences Inc., with effect from 15 December 2014. Dr. Platzer is a board certified physician in internal medicine, hematology and medical oncology. Previously, Dr. Platzer was business director of oncology, global strategic marketing and therapeutic area head of oncology at Roche, Basel, where he also served as medical director in oncology and global development project leader. Dr. Platzer is a director of Swiss Business Angel Groups, StartAngels and BioBAC and has served as a pharmaceutical industry expert on the board of directors of multiple biotech companies. Dr. Platzer co-founded and currently serves as an investment advisor to HBM Partners AG, a global leader in healthcare investing. At HBM, he focuses on private equity and venture capital investments in start-up companies, specifically in the areas of oncology, inflammatory diseases and CNS. He is the author of more than 35 scientific papers. Dr. Platzer graduated from the Medical School and the Institute of Clinical Immunology and Rheumatology of the University of Erlangen in 1979, where he later also received the "Dr. med. habil." (M.D.,Ph.D.).

Bradley Thompson

Dr. Bradley Thompson has been appointed as Independent Director of Aptose Biosciences Inc., with effect from June 27, 2013. Dr. Thompson is an experienced and respected biotechnology professional who has held the positions of Chairman of the Board and President and Chief Executive Officer of Oncolytics Biotech Inc. since April 1999. Prior to his role with Oncolytics Dr. Thompson was the Chief Executive Officer of Synsorb Biotech from 1994 to 1999. Dr. Thompson is also currently a board member of Immunovaccine Inc. He received his PhD from the University of Western Ontario in the Department of Microbiology and Immunology.

Mark Vincent

Dr. Mark D. Vincent, M.D., is Independent Director of Aptose Biosciences Inc. Dr. Vincent is a Professor of Oncology at the University of Western Ontario and a staff medical oncologist at the London Regional Cancer Program. Dr. Vincent is also the co-founder and Chief Executive Officer of Sarissa, Inc. since 2000. Physician; medical oncologist, London Regional Cancer Program Cancer Care Ontario (1990 to present) (cancer care facility).

Warren Whitehead

Mr. Warren Whitehead is Independent Director of Aptose Biosciences Inc. Mr. Whitehead is a CPA (CMA) who has held senior financial management positions in several biotechnology and pharmaceutical companies. Currently he is the Chief Financial Officer of Amorfix Life Sciences Ltd. Prior to this, he served as Chief Financial Officer of ARIUS Research Inc., providing financial guidance and leadership during the acquisition of ARIUS by Roche in 2008. Prior to ARIUS, Mr. Whitehead was Chief Financial Officer at Labopharm Inc., where he completed a series of public equity financings and a listing on NASDAQ. He is currently the Chairman of the Board of Directors of PlantForm Corporation, a life sciences company that develops biosimilar antibody drugs for treatment of cancer and other critical illnesses.

Basic Compensation

Name Fiscal Year Total

William Rice

2,330,860

Gregory Chow

664,443

Denis Burger

--

Erich Platzer

--

Bradley Thompson

--

Mark Vincent

--

Warren Whitehead

--
As Of  31 Dec 2014